AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
08.07.2015 14:21:38
|
AstraZeneca, Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial
(RTTNews) - AstraZeneca Pharmaceuticals Co., Ltd. (AZN, AZN.L) and Ironwood Pharmaceuticals, Inc. (IRWD) reported top-line data demonstrating linaclotide met all primary and secondary endpoints, covering multiple abdominal and constipation symptoms, in a Phase III clinical trial of adults with irritable bowel syndrome with constipation or IBS-C.
The trial was conducted primarily in China. The companies intend to file in early 2016 for China Food and Drug Administration approval to market linaclotide.
Linaclotide is currently approved in the U.S. for the treatment of adults with IBS-C or chronic idiopathic constipation and in several other countries for adults with IBS-C.
The double-blind, placebo-controlled Phase III clinical trial randomized 839 adults with IBS-C in China, Australia, Canada, New Zealand and the U.S.
Patients were randomized 1:1 to receive either 290 mcg of linaclotide, or placebo, for 12 weeks. The primary endpoints used in this trial were similar to those previously used to support approval of linaclotide in the European Union.
The co-primary endpoints of the trial were 12-Week Abdominal Pain/Discomfort Responder, and 12-Week IBS Degree of Relief Responder.
Top-line data from the Phase III trial indicate linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients for both co-primary endpoints.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
31.03.25 |
Börse New York: NASDAQ 100 am Nachmittag in Rot (finanzen.at) | |
31.03.25 |
Börse New York in Rot: NASDAQ 100 verbucht mittags Verluste (finanzen.at) | |
31.03.25 |
Angespannte Stimmung in New York: NASDAQ 100 beginnt die Montagssitzung mit Verlusten (finanzen.at) | |
28.03.25 |
Angespannte Stimmung in New York: NASDAQ 100 schwächelt zum Handelsende (finanzen.at) | |
28.03.25 |
NASDAQ 100 aktuell: NASDAQ 100 sackt nachmittags ab (finanzen.at) | |
28.03.25 |
Anleger in New York halten sich zurück: NASDAQ 100 präsentiert sich am Mittag schwächer (finanzen.at) | |
28.03.25 |
Handel in New York: NASDAQ 100 sackt zum Start ab (finanzen.at) | |
27.03.25 |
Schwacher Handel: NASDAQ 100 zeigt sich zum Handelsende leichter (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 67,00 | -1,47% |
|
Ironwood Pharmaceuticals Inc (A) | 1,35 | 0,00% |
|